Cytokinetics | CYTK - Assets


Cytokinetics reported $1.27B in Assets for its fiscal quarter ending in March of 2026.





Assets Change Date
Acadia Pharmaceuticals USD 1.74B 137.67M Jun/2026
Amgen USD 95.64B 3.14B Jun/2026
Arca Biopharma USD 504.48M 15.86M Mar/2026
Bayer EUR 107.94B 3.4B Mar/2026
Biogen USD 32.09B 2.6B Jun/2026
Brainstorm Cell Therapeutics USD 755K 267K Mar/2026
Bristol-Myers Squibb USD 87.63B 1.16B Jun/2026
Capricor Therapeutics USD 326.28M 29.66M Mar/2026
Cytokinetics USD 1.27B 151.06M Mar/2026
Eisai JPY 1.56T 108.98B Jun/2026
Eli Lilly USD 142.28B 25.71B Jun/2026
Exelixis USD 2.59B 250.83M Mar/2026
Geron USD 519.01M 15.11M Jun/2026
Halozyme Therapeutics USD 2.67B 147.4M Mar/2026
Ionis Pharmaceuticals USD 2.99B 455.5M Jun/2026
Ligand Pharmaceuticals USD 1.53B 28.53M Mar/2026
Merck USD 128.68B 8.18B Mar/2026
Novartis USD 122.03B 3.5B Jun/2026
Pfizer USD 201.13B 6.49B Jun/2026
Regeneron Pharmaceuticals USD 41.73B 861.8M Jun/2026
Roche Holding CHF 98.2B 2.5B Jun/2026
Sanofi EUR 129.06B 1.04B Jun/2026